Rovi targets 2030 CDMO growth. Rovi stock sits 31.86 percent below its high

Published on 10/13/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi reported EUR 357.00 million revenue in first-half 2026, up 13.00 percent. Rovi stock costs EUR 59.08 on October 13, 2026 versus EUR 58.50.

Rovi is targeting a larger contract development and manufacturing business by 2030.
First-half 2026 revenue reached EUR 357.00 million, up 13.00 percent year over year.
Rovi stock was EUR 59.08 at Lang & Schwarz on October 13, 2026, 31.86 percent below its 52-week high.
Rovi is scheduled to publish nine-month 2026 results on November 5, 2026.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi stock (ISIN ES0157261019) was trading at EUR 59.08 at Lang & Schwarz on October 13, 2026 at 9:01 a.m. CEST, standing 0.99 percent above the Xetra close of October 12, 2026 at EUR 58.50 and 31.86 percent below the EUR 86.70 52-week high. On October 6, 2026, Estrategias de Inversión reported that Rovi expects operating revenue from its contract development and manufacturing organization business to reach 1.50 to 1.80 times its current level by 2030.

Three milestones since May

On May 6, 2026, Rovi reported first-quarter net profit of EUR 9.40 million, according to MarketScreener. On July 23, 2026, Rovi reported first-half revenue of EUR 357.00 million, up 13.00 percent year over year, while operating revenue reached EUR 344.20 million, up 9.00 percent, according to Yahoo Finance. On October 6, 2026, the company highlighted CDMO revenue of EUR 106.30 million in the first half, a 38.00 percent increase, in the strategy coverage from Estrategias de Inversión.

What drives the next leg

The CDMO expansion is supported by Rovi's Phoenix manufacturing facility and by demand for sterile fill-and-finish services. In the first half of 2026, Okedi sales rose 27.00 percent to EUR 34.00 million, while heparin revenue fell 4.00 percent to EUR 130.10 million, according to Yahoo Finance. The contrast matters because the fast-growing manufacturing unit is expanding while the established heparin franchise remains exposed to inventory levels and pricing pressure.

Rovi also reported adjusted EBITDA of EUR 58.80 million in the first half of 2026 after excluding a EUR 62.40 million bargain purchase gain linked to Phoenix. Cash flow from operating activities reached EUR 94.30 million, compared with EUR 28.00 million in the first half of 2025, giving the expansion plan a stronger internal funding base.

Results date is November 5

Rovi's investor calendar lists November 5, 2026, for its first nine months 2026 financial results, per the company's Rovi investor-relations page. The report will offer the next quantified test of whether CDMO growth can offset the pressure on heparin revenue and the scheduled end of the Neparvis contract.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.